Current Editions
An analysis of the targets companies are pursuing to retain muscle while losing fat
Product Development
Targeted protein degraders and selective small molecules face off against SMARCA4-mutant cancers at AACR
Product Development
With U.S. institutions under strain, Europe must act decisively to support innovation and secure a bigger role in biotech’s future
BioCentury Commentary
Four tumor atlases point to target vulnerabilities and predictive signatures in epithelial ovarian cancers
Discovery & Translation
Product Development
Special guests join BioCentury to discuss how industry can navigate the new complexity. Plus: the Belgian biotech ecosystem
Data Byte
Total CDER approvals stand at 10 so far this year, 50% less than at this time last year
At least 13 companies described preclinical KRAS degraders at the meeting
Compounded GLP-1s impact 1Q25 sales growth
Discovery & Translation
BioCentury’s roundup of translational innovations also includes microglia replacement for neurological disorders and enhanced mRNA vaccine efficacy
Regulation
About-face by FDA on bladder cancer application stuns Immunitybio
XBI falls as investors, biotech CEOs weigh whether approval bar will rise
Politics, Policy & Law
Trade associations and biopharma CEOs are mobilizing to oppose the drug pricing policy
Finance
How the corporate VC is evolving its portfolio strategy
Plus: Deerfield raises $600M for next vehicle, Vivo’s refreshed evergreen fund, and more
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Management Tracks
BioCentury ISSN 1097-7201